Challenges With Postoperative Posterior Segment Inflammation

This activity is supported by an independent medical education grant from EyePoint Pharmaceuticals.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Describe the limitations of postoperative topical corticosteroids
• Categorize the novel approaches to manage and/or prevent posterior inflammation that may improve efficacy and adherence
• Interpret pivotal clinical trial data leading to FDA approvals of sustained-release devices for posterior segment inflammation
• Create personalized treatment plans based on patient needs and preferences
• Discuss the literature on alternative therapies, including their safety, efficacy, and ideal patient selection

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

David A. Eichenbaum, MD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, EyePoint Pharmaceuticals, Genentech, Gyroscope, IvericBio, Kodiak, Notal Vision, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, AsclepiX, Bayer, Chengdu, Gemini, Genentech, Gyroscope, lonis, lvericBio, Kodiak, Mylan, NGM, Novartis, Opthea, and Regeneron Pharmaceuticals. Speaker’s Bureau: Allergan, Bayer, DORC, EyePoint Pharmaceuticals, Genentech, and Novartis.

Daniel F. Kiernan, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, EyePoint Pharmaceuticals, and Physician Recommended Nutraceuticals. Grant/Research Support: EyePoint Pharmaceuticals and Gyroscope. Speaker’s Bureau: Alimera, Allergan, EyePoint Pharmaceuticals, Mallinckrodt, Novartis, Physician Recommended Nutraceuticals, Regeneron Pharmaceuticals, and Spark Therapeutics.

The Evolve staff and planners have no financial relationships with commercial interests.
Mark Goerlitz-Jessen, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or EyePoint Pharmaceuticals.